retatrutide clinical trial weight loss results Eli Lilly's shows promising in phase 3 Eli Lilly's triple agonist, retatrutide,

For those who might consider alternatives, we will discuss other medications and treatments

Hair Thinning One possible side effect of taking GLP-1 drugs is hair thinning

If we could get oral versions on the market, maybe the prices would come down. Amgen, meanwhile, thinks a less frequently taken medication could be convenient for some patients

As the market becomes more receptive to the concept of metabolic wellness and the emerging opportunity for biosimilar production, there is likely to be a positive impact on affordability and increased access to the market

The head-to-head trial against tirzepatide (NCT06662383) is particularly interesting

The triple mechanism requires careful titration despite the compressed timeline